Drug intelligence / Profile preview

BRP-030

Development stage: Preclinical
Lead developer: BoomRay Pharmaceuticals
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules

Overview

BRP-030 is a therapeutic radiopharmaceutical under preclinical development for the treatment of neoplasms, specifically solid tumors. It was initially developed by Suzhou Yao Ming Bo Rui Biotechnology. The drug is designed to deliver targeted radiation therapy to cancer cells, though specific molecular targets and mechanisms of action have not been disclosed in public sources as of June 2025[1][3]. There is no evidence that it has reached clinical trials or received regulatory approval.

Beyond the preview

Go deeper on BRP-030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRP-030.

Explore the full profile